Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 9/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 9/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 9/20 | 0.35 |
| ▸ | KDR | P35968 | 8/20 | 0.35 |
| ▸ | ALPG | P10696 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10292434 | 0.87 | FPR2 (0.45) | FPR2RAB9AL3MBTL1ALPGPLAA | |
| SCHEMBL4075983 | 0.82 | AGTR1 (0.39) | RAB9AL3MBTL1SMN1; SMN2 | |
| SCHEMBL4071647 | 0.80 | ALDH1A1 (0.38) | RAB9AL3MBTL1FGFR1FGFR2FGFR4 | |
| SCHEMBL4070185 | 0.75 | ALDH1A1 (0.38) | RAB9AL3MBTL1FGFR1FGFR2FGFR4 | |
| SCHEMBL10261857 | 0.74 | FPR2 (0.45) | FPR2L3MBTL1ALPGPLAAALPL | |
| SCHEMBL11936765 | 0.74 | RAB9A (0.39) | FPR2RAB9AL3MBTL1ALPGCA12 | |
| SCHEMBL15199174 | 0.74 | RAB9A (0.38) | FPR2RAB9AL3MBTL1ALPGPLAA | |
| SCHEMBL4215152 | 0.73 | SORD (0.42) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL2693461 | 0.73 | TSHR (0.41) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL11938341 | 0.73 | FPR2 (0.43) | FPR2ALPGCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325992-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2055705-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | Ono Pharmaceutical CO., LTD. (JP) | 2009-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325992-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | CXCR4, CXCL12, CXCR1 | FPR2 1143/4885RAB9A 476/4885L3MBTL1 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.